Clonal Hematopoiesis and Blood-Cancer Risk Inferred from Blood DNA Sequence
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Cancers arise from multiple acquired mutations, which presumably occur over many years. Early stages in cancer development might be present years before cancers become clinically apparent. METHODS: We analyzed data from whole-exome sequencing of DNA in peripheral-blood cells from 12,380 persons, unselected for cancer or hematologic phenotypes. We identified somatic mutations on the basis of unusual allelic fractions. We used data from Swedish national patient registers to follow health outcomes for 2 to 7 years after DNA sampling. RESULTS: Clonal hematopoiesis with somatic mutations was observed in 10% of persons older than 65 years of age but in only 1% of those younger than 50 years of age. Detectable clonal expansions most frequently involved somatic mutations in three genes (DNMT3A, ASXL1, and TET2) that have previously been implicated in hematologic cancers. Clonal hematopoiesis was a strong risk factor for subsequent hematologic cancer (hazard ratio, 12.9; 95% confidence interval, 5.8 to 28.7). Approximately 42% of hematologic cancers in this cohort arose in persons who had clonality at the time of DNA sampling, more than 6 months before a first diagnosis of cancer. Analysis of bone marrow-biopsy specimens obtained from two patients at the time of diagnosis of acute myeloid leukemia revealed that their cancers arose from the earlier clones. CONCLUSIONS: Clonal hematopoiesis with somatic mutations is readily detected by means of DNA sequencing, is increasingly common as people age, and is associated with increased risks of hematologic cancer and death. A subset of the genes that are mutated in patients with myeloid cancers is frequently mutated in apparently healthy persons; these mutations may represent characteristic early events in the development of hematologic cancers. (Funded by the National Human Genome Research Institute and others.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“CHIP carriers have an about 13-fold increased risk of developing myeloid hematological malignancies and an increased risk of all-cause mortality, largely due to cardiovascular disease and stroke.1, 2, 3, 4”
From Aging drives Tet2 +/− clonal hematopoiesis via IL-1 signaling (2023) · cites this paper as [1]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clonal expansion of blood cells, called clonal hematopoiesis (CH), increases in prevalence with age and is associated with increased risk of hematologic malignancies, but also unexpectedly with increased risk of cardiovascular disease20,21, likely through inflammatory effects of mutant cells22.”
From Somatic cancer variants enriched in Alzheimer’s disease microglia-like cells drive inflammatory and proliferative states (2026) · cites this paper as [20]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This state of abnormal HSC expansion without overt hematologic disease is known as clonal hematopoiesis (CH), and is associated with increased risk of cardiovascular events and blood cancers (3)(4)(5).”
From Txnip Enhances Fitness of Dnmt3a -Mutant Hematopoietic Stem Cells via p21 (2022) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“CHIP carriers have an about 13-fold increased risk of developing myeloid hematological malignancies and an increased risk of all-cause mortality, largely due to cardiovascular disease and stroke.1, 2, 3, 4”
From Aging drives Tet2 +/− clonal hematopoiesis via IL-1 signaling (2023) · cites this paper as [1]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Loss-of-function heterozygous mutations in epigenetic regulators DNMT3A (cytosine methyltransferase) and TET2 (methylcytosine dioxygenase) are the most frequently detected mutations in CHIP, accounting for about 50% to 60% and 10% to 30% of mutations found in CHIP carriers, respectively.1, 2, 3,7,8”
From Aging drives Tet2 +/− clonal hematopoiesis via IL-1 signaling (2023) · cites this paper as [1]
Experimental — accuracy not yet measured
21 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stem cells, cancer, and cancer stem cells
Reya, T., Morrison, S. J., Clarke, M. F., & Weissman, I. L. (2001) · Nature · doi:10.1038/35102167 · Cited by 9,738
Nowell, P. C. (1976) · Science · doi:10.1126/science.959840 · Cited by 6,471
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
The Cancer Genome Atlas Research Network (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1301689 · Cited by 5,078
A Gain-of-Function Mutation of JAK2 in Myeloproliferative Disorders
Kralovics, R., Passamonti, F., Buser, A. S., Teo, S.-S., Tiedt, R., Passweg, J. R., Tichelli, A., Cazzola, M., & Skoda, R. C. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051113 · Cited by 3,470 · cited 15×
“Busque L, Patel JP, Figueroa ME, et al. Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis.”
BackgroundInfluentialDiscovery and saturation analysis of cancer genes across 21 tumour types
Lawrence, M. S., Stojanov, P., Mermel, C. H., Robinson, J. T., Garraway, L. A., Golub, T. R., Meyerson, M., Gabriel, S. B., Lander, E. S., & Getz, G. (2014) · Nature · doi:10.1038/nature12912 · Cited by 3,096
Self-citationCOSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer
Forbes, S. A., Bindal, N., Bamford, S., Cole, C., Kok, C. Y., Beare, D., Jia, M., Shepherd, R., Leung, K., Menzies, A., et al. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq929 · Cited by 2,278
Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing
Ding, L., Ley, T. J., Larson, D. E., Miller, C. A., Koboldt, D. C., Welch, J. S., Ritchey, J. K., Young, M. A., Lamprecht, T., McLellan, M. D., et al. (2012) · Nature · doi:10.1038/nature10738 · Cited by 1,993
DNMT3A Mutations in Acute Myeloid Leukemia
Ley, T. J., Ding, L., Walter, M. J., McLellan, M. D., Lamprecht, T., Larson, D. E., Kandoth, C., Payton, J. E., Baty, J., Welch, J., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1005143 · Cited by 1,983
Mutation in TET2 in Myeloid Cancers
Delhommeau, F., Dupont, S., Valle, V. D., James, C., Trannoy, S., Massé, A., Kosmider, O., Le Couedic, J.-P., Robert, F., Alberdi, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810069 · Cited by 1,776
Genome-wide association analysis identifies 13 new risk loci for schizophrenia
Multicenter Genetic Studies of Schizophrenia Consortium, Ripke, S., Psychosis Endophenotypes International Consortium, Wellcome Trust Case Control Consortium 2, O'Dushlaine, C., Chambert, K., Moran, J. L., Kähler, A. K., Akterin, S., Bergen, S. E., et al. (2013) · Nature Genetics · doi:10.1038/ng.2742 · Cited by 1,496
Self-citation
Cited by
Items 801–900 of 1,031
Blood-Based Analysis of Circulating Cell-Free DNA and Tumor Cells for Early Cancer Detection
Pantel, K. (2016) · PLoS Medicine · doi:10.1371/journal.pmed.1002205 · Cited by 60
Frailty assessment in the care of older people with haematological malignancies
Goede, V., Neuendorff, N. R., Schulz, R. J., Hormigo, A.-I., Martínez-Peromingo, F. J., & Córdoba, R. (2021) · The Lancet Healthy Longevity · doi:10.1016/s2666-7568(21)00184-7 · Cited by 59
Kimishima, Y., Misaka, T., Yokokawa, T., Wada, K., Ueda, K., Sugimoto, K., Minakawa, K., Nakazato, K., Ishida, T., Oshima, M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26435-0 · Cited by 59
Provencio, M., Calvo, V., Romero, A., Spicer, J. D., & Cruz‐Bermúdez, A. (2022) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_358995 · Cited by 65
Inflammation as a driver of clonal evolution in myeloproliferative neoplasm
Fleischman, A. G. (2015) · Mediators of Inflammation · doi:10.1155/2015/606819 · Cited by 53
Somatic TP53 mutations characterize preleukemic stem cells in acute myeloid leukemia
Lal, R., Lind, K., Heitzer, E., Ulz, P., Aubell, K., Kashofer, K., Middeke, J. M., Thiede, C., Schulz, E., Rosenberger, A., et al. (2017) · Blood · doi:10.1182/blood-2016-11-751008 · Cited by 57
Preleukemic Hematopoietic Stem Cells in Human Acute Myeloid Leukemia
Corces, M. R., Chang, H. Y., & Majeti, R. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00263 · Cited by 61
“The most frequently mutated genes in CHIP are DNMT3A and TET2, echoing their role during the preleukemic phase of AML (43, 44, 50).”
BackgroundAutocrine Tnf signaling favors malignant cells in myelofibrosis in a Tnfr2-dependent fashion
Heaton, W. L., Senina, A. V., Pomicter, A. D., Salama, M. E., Clair, P. M., Yan, D., Bell, R. N., Gililland, J. M., Prchal, J. T., O’Hare, T., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0131-z · Cited by 61
Multimodality Cardiac Imaging in the Era of Emerging Cancer Therapies
Biersmith, M. A., Tong, M., Guha, A., Simonetti, O. P., & Addison, D. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.013755 · Cited by 57
“Though a mechanistic link between CHIP and cardiac mortality has yet to be definitively established, it is plausible that CHIP alleles confer cardiovascular risk via atherosclerosis mechanisms.(83,84) The optimal management strategies require further investigation.”
BackgroundHarnessing cell-free DNA: plasma circulating tumour DNA for liquid biopsy in genitourinary cancers
Maia, M. C., Salgia, M. M., & Pal, S. K. (2020) · Nature Reviews Urology · doi:10.1038/s41585-020-0297-9 · Cited by 64
TET2: A cornerstone in normal and malignant hematopoiesis
Kunimoto, H., & Nakajima, H. (2020) · Cancer Science · doi:10.1111/cas.14688 · Cited by 61
Somatic Mutations in Cardiovascular Disease
Heimlich, J. B., & Bick, A. G. (2022) · Circulation Research · doi:10.1161/circresaha.121.319809 · Cited by 59
Bronkhorst, A. J., Ungerer, V., & Holdenrieder, S. (2019) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2019.1700902 · Cited by 63
Williams, N., Lee, J., Moore, L., Baxter, E. J., Hewinson, J., Dawson, K. J., Menzies, A., Godfrey, A. L., Green, A. R., Campbell, P. J., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.11.09.374710 · Cited by 53
Genetic profiling of cancer with circulating tumor DNA analysis
Lu, L., Bi, J., & Bao, L. (2018) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2017.11.006 · Cited by 56
Segura-Díaz, A., Stuckey, R., Florido, Y., González-Martín, J. M., López-Rodríguez, J. F., Sánchez-Sosa, S., González-Pérez, E., Perdomo, M. N. S., Perera, M. D. M., de la Iglesia, S., et al. (2020) · Cancers · doi:10.3390/cancers12040934 · Cited by 59
Loss of Y and clonal hematopoiesis in blood—two sides of the same coin?
Ljungström, V., Mattisson, J., Halvardson, J., Pandzic, T., Davies, H., Rychlicka-Buniowska, E., Danielsson, M., Lacaze, P. A., Cavelier, L. B., Dumanski, J. P., et al. (2021) · Leukemia · doi:10.1038/s41375-021-01456-2 · Cited by 55
Germline TP53 pathogenic variants and breast cancer: A narrative review
Blondeaux, E., Arecco, L., Punie, K., Graffeo, R., Toss, A., Angelis, C. D., Trevisan, L., Buzzatti, G., Linn, S. C., Dubsky, P. C., et al. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102522 · Cited by 66
Mitochondrial metabolism sustains DNMT3A-R882-mutant clonal haematopoiesis
Gozdecka, M., Dudek, M., Wen, S., Gu, M., Stopforth, R. J., Rak, J. M., Damaskou, A., Grice, G. L., McLoughlin, M. A., Bond, L., et al. (2025) · Nature · doi:10.1038/s41586-025-08980-6 · Cited by 67
Accumulation of DNA damage in the aged hematopoietic stem cell compartment
Beerman, I. (2017) · Seminars in Hematology · doi:10.1053/j.seminhematol.2016.11.001 · Cited by 57
“This interpretation is supported by publications in murine models in which loss of Dnmt3a or Tet2 confers enhanced self-renewal potential to HSCs (77-81).”
BackgroundAging- and Senescence-associated Changes of Mesenchymal Stromal Cells in Myelodysplastic Syndromes
Mattiucci, D., Maurizi, G., Leoni, P., & Poloni, A. (2018) · Cell Transplantation · doi:10.1177/0963689717745890 · Cited by 56
Impact of somatic and germline mutations on the outcome of systemic mastocytosis
Muñoz-González, J. I., Jara-Acevedo, M., Alvarez-Twose, I., Merker, J. D., Teodosio, C., Hou, Y., Henriques, A., Roskin, K. M., Sanchez-Muñoz, L., Tsai, A. G., et al. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018020628 · Cited by 55
Carlston, C. M., O’Donnell‐Luria, A., Underhill, H. R., Cummings, B. B., Weisburd, B., Minikel, E. V., Birnbaum, D. P., Tvrdik, T., MacArthur, D. G., & Mao, R. (2017) · Human Mutation · doi:10.1002/humu.23203 · Cited by 56
“Hematopoietic clonal expansion of cells with ASXL1 pathogenic variants has been reported as a frequent event acquired with aging (Genovese et al. 2014; Jaiswal et al. 2014; Xie et al. 2014).”
InfluentialRenosi, F., Roggy, A., Giguelay, A., Soret, L., Viailly, P., Cheok, M. H.-C., Biichlé, S., Angelot‐Delettre, F., Asnafi, V., Macintyre, E. A., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020003359 · Cited by 55
“10).(70,71) At the diagnosis of neoplasm, VAF reached higher levels, because of clonal evolution.”
BackgroundDevelopmental and temporal characteristics of clonal sperm mosaicism
Yang, X., Breuss, M. W., Xu, X., Antaki, D., James, K. N., Stanley, V., Ball, L., George, R. D., Wirth, S. A., Cao, B., et al. (2021) · Cell · doi:10.1016/j.cell.2021.07.024 · Cited by 57
Knoechel, B., Bhatt, A. S., Li, P., Pedamallu, C. S., Severson, E. A., Gutiérrez, A., Dorfman, D. M., Kuo, F. C., Kluk, M., Kung, A. L., et al. (2015) · Molecular Case Studies · doi:10.1101/mcs.a000539 · Cited by 61
“The latter observation strongly suggests that this patient’s ETP-ALL arose out of a background of clonal hematopoiesis, a common condition in older adults (Genovese et al. 2014; Jaiswal et al. 2014).”
BackgroundBone marrow inflammation in haematological malignancies
de Jong, M. M. E., Chen, L., Raaijmakers, M. H. G. P., & Cupedo, T. (2024) · Nature reviews. Immunology · doi:10.1038/s41577-024-01003-x · Cited by 54
“CHIP is common, affecting approximately 10–15% of individuals over 70 years old, and is associated with an increased risk for cardiovascular disease and myeloid malignancies 150,151 .”
The Role of ctDNA in Gastric Cancer
Mencel, J., Slater, S., Cartwright, E., & Starling, N. (2022) · Cancers · doi:10.3390/cancers14205105 · Cited by 58
“This somatic blood cell clonally derived variant represents a false positive result when using ctDNA-based sequencing [23].”
BackgroundBhatnagar, B., Eisfeld, A., Nicolet, D., Mrózek, K., Blachly, J. S., Orwick, S. J., Lucas, D. M., Kohlschmidt, J., Blum, W. G., Kolitz, J. E., et al. (2016) · British Journal of Haematology · doi:10.1111/bjh.14254 · Cited by 56
Clinical Significance of DNA Variants in Chronic Myeloid Neoplasms
McClure, R. F., Ewalt, M. D., Crow, J., Temple‐Smolkin, R., Pullambhatla, M., Sargent, R. L., & Kim, A. S. (2018) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2018.07.002 · Cited by 57
Immunosenescence and lymphomagenesis
Mancuso, S., Carlisi, M., Santoro, M., Napolitano, M., Raso, S., & Siragusa, S. M. (2018) · Immunity & Ageing · doi:10.1186/s12979-018-0130-y · Cited by 57
Clonal Hematopoiesis of Indeterminate Potential in Patients with Solid Tumor Malignancies
Marshall, C. H., Gondek, L. P., Luo, J., & Antonarakis, E. S. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-0985 · Cited by 58
Uddin, M. M., Saadatagah, S., Niroula, A., Yu, B., Hornsby, W., Ganesh, S., Lannery, K., Schuermans, A., Honigberg, M. C., Bick, A. G., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-52302-9 · Cited by 64
“The fi ndings were consistent with our primary analysis (Supplementary Data 3 and 4).”
Rojek, K., Nickels, E. M., Neistadt, B., Marquez, R., Wickrema, A., Artz, A. S., van Besien, K., Larson, R. A., Lee, M. K., Segal, J. P., et al. (2016) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2016.08.002 · Cited by 53
“5% of those 70 to 79 years old, or in 10% of subjects >65 years old [5,6].”
BackgroundResultInfluentialImplications of molecular genetic diversity in myelodysplastic syndromes
Bejar, R. L. (2016) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000313 · Cited by 58
Epigenetics in normal and malignant hematopoiesis: An overview and update 2017
Goyama, S., & Kitamura, T. (2017) · Cancer Science · doi:10.1111/cas.13168 · Cited by 58
Aging, hematopoiesis, and the myelodysplastic syndromes
Chung, S. S., & Park, C. Y. (2017) · Blood Advances · doi:10.1182/bloodadvances.2017009852 · Cited by 58
“Given the recent demonstrations that early driver mutations in mature non-Hodgkin lymphomas can arise 76 American Society of Hematology in HSCs,52 this suggests that similar selection pressures on HSCs during aging may promote the development of many hematologic cancers in addition to the myeloid malignancies, a specu…”
BackgroundBoileau, M., Shirinian, M., Gayden, T., Harutyunyan, A. S., Chen, C. C. L., Mikael, L. G., Duncan, H. M., Neumann, A. L., Arreba-Tutusaus, P., Jay, N. D., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10705-z · Cited by 55
Franzini, A., Pomicter, A. D., Yan, D., Khorashad, J. S., Tantravahi, S. K., Than, H., Ahmann, J. M., O’Hare, T., & Deininger, M. W. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000585 · Cited by 63
Clonal hematopoiesis in elderly twins: concordance, discordance, and mortality
Hansen, J. W., Pedersen, D. A., Larsen, L. A., Husby, S., Clemmensen, S. B., Hjelmborg, J., Favero, F., Weischenfeldt, J., Christensen, K., & Grønbæk, K. (2020) · Blood · doi:10.1182/blood.2019001793 · Cited by 53
The new biology of PTCL‐NOS and AITL: current status and future clinical impact
Timmins, M. A., Wagner, S. D., & Ahearne, M. J. (2020) · British Journal of Haematology · doi:10.1111/bjh.16428 · Cited by 55
Translating recent advances in the pathogenesis of acute myeloid leukemia to the clinic
Bewersdorf, J. P., & Abdel-Wahab, O. I. (2022) · Genes & Development · doi:10.1101/gad.349368.122 · Cited by 57
“While SF3B1 mutations in MDS have been associated with a favorable prognosis, U2AF1 and SRSF2 mutations are enriched in high-risk MDS and AML and confer an adverse prognosis (Thol et al. 2012; Bejar et al. 2015; Ohgami et al. 2015).”
BackgroundInfluentialPons-Belda, O. D., Fernandez-Uriarte, A., & Diamandis, E. P. (2021) · Diagnostics · doi:10.3390/diagnostics11122171 · Cited by 52
Bone Marrow Immune Microenvironment in Myelodysplastic Syndromes
Kouroukli, O., Symeonidis, A. S., Foukas, P. G., Maragkou, M., & Kourea, E. P. (2022) · Cancers · doi:10.3390/cancers14225656 · Cited by 58
Clonal haematopoiesis in cardiovascular disease: prognostic role and novel therapeutic target
Schuermans, A., & Honigberg, M. C. (2025) · Nature Reviews Cardiology · doi:10.1038/s41569-025-01148-9 · Cited by 60
“In their respective studies, Genovese et al. 8 and Jaiswal et al. 9 had poor coverage for approximately 50% of TET2 and ASXL1 mutations, leading to fewer CHIP calls and potential under-representation of these genes.”
InfluentialWakita, S., Yamaguchi, H., Ueki, T., Usuki, K., Kurosawa, S., Kobayashi, Y., Kawata, E., Tajika, K., Gomi, S., Koizumi, M., et al. (2015) · Leukemia · doi:10.1038/leu.2015.288 · Cited by 57
Chang, Y., You, X., Kong, G., Ranheim, E. A., Wang, J., Du, J., Liu, Y., Zhou, Y., Ryu, M.-J., & Zhang, J. (2015) · Leukemia · doi:10.1038/leu.2015.85 · Cited by 55
Inferring mutational timing and reconstructing tumour evolutionary histories
Turajlic, S., McGranahan, N., & Swanton, C. (2015) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2015.03.005 · Cited by 55
“In two separate studies of WES of peripheral blood cells involving over 30, 000 healthy individuals clonal haematopoiesis was shown to increase with age [81,82].”
BackgroundAcute myeloid leukemia derived from lympho-myeloid clonal hematopoiesis
Thol, F., Klesse, S., Köhler, L., Gabdoulline, R., Kloos, A., Liebich, A., Wichmann, M., Chaturvedi, A., Fabisch, J., Gaidzik, V. I., et al. (2017) · Leukemia · doi:10.1038/leu.2016.345 · Cited by 54
Slade, M., DiPersio, J. F., Westervelt, P., Vij, R., Schroeder, M. A., & Romee, R. (2017) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2017.06.019 · Cited by 52
Lin, M., Hou, H., Tsai, C., Wu, S., Kuo, Y., Tseng, M., Liu, M.-C., Liu, C., Chou, W., Chen, C., et al. (2018) · Clinical Epigenetics · doi:10.1186/s13148-018-0476-1 · Cited by 57
Current status and trends in the diagnostics of AML and MDS
Shumilov, E., Flach, J., Kohlmann, A., Banz, Y., Bonadies, N., Fiedler, M., Pabst, T., & Bacher, U. (2018) · Blood Reviews · doi:10.1016/j.blre.2018.04.008 · Cited by 55
Klepin, H. D., Estey, E. H., & Kadia, T. M. (2019) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_239097 · Cited by 57
Short, N. J., & Ravandi, F. (2019) · Haematologica · doi:10.3324/haematol.2018.208454 · Cited by 58
Wong, W. H., Bhatt, S., Trinkaus, K., Pusic, I., Elliott, K., Mahajan, N., Wan, F., Switzer, G. E., Confer, D. L., DiPersio, J., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aax6249 · Cited by 55
Pellini, B., Pejovic, N., Feng, W., Earland, N. J., Harris, P. K. W., Usmani, A., Szymanski, J. J., Qaium, F., Mudd, J. L., Petty, M., et al. (2021) · JCO Precision Oncology · doi:10.1200/po.20.00276 · Cited by 59
Cohesin mutations in myeloid malignancies
Jann, J.-C., & Tóthová, Z. (2021) · Blood · doi:10.1182/blood.2019004259 · Cited by 55
TP53 in Acute Myeloid Leukemia: Molecular Aspects and Patterns of Mutation
George, B., Kantarjian, H. M., Baran, N., Krocker, J. D., & Rios, A. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910782 · Cited by 61
Miller, P. G., Sperling, A. S., Mayerhofer, C., McConkey, M. E., Ellegast, J. M., Silva, C. D., Cohen, D. N., Wang, C., Sharda, A., Yan, N., et al. (2023) · Blood · doi:10.1182/blood.2023020331 · Cited by 54
Genetic variation across and within individuals
Yu, Z., Coorens, T. H. H., Uddin, M. M., Ardlie, K., Lennon, N. J., & Natarajan, P. (2024) · Nature Reviews Genetics · doi:10.1038/s41576-024-00709-x · Cited by 58
“…and homozygous, respectively, whereas the smaller distribution, close to 0%, represents putative somatic variants (present in some cells) 152 . c , Analogous aspects of studies on germline and somatic variants: rates of mutation acquisition across generations (germline) and individual…”
BackgroundBrunetti, L., Battista, V. D., Venanzi, A., Schiavoni, G., Martelli, M. P., Ascani, S., Mecucci, C., Tiacci, E., & Falini, B. (2017) · Leukemia · doi:10.1038/leu.2017.38 · Cited by 52
Biechonski, S., Yassin, M., & Milyavsky, M. (2017) · Carcinogenesis · doi:10.1093/carcin/bgx002 · Cited by 55
Takahashi, K., Hu, B., Wang, F., Yan, Y., Kim, E., Vitale, C., Patel, K. P., Strati, P., Gumbs, C. E., Little, L., et al. (2018) · Blood · doi:10.1182/blood-2017-11-817296 · Cited by 55
Czyż, A., & Nagler, A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20215362 · Cited by 52
“CHIP is observed in approximately 10% of normal individuals older than 65–70 years of age, as was clearly demonstrated by two research groups which analyzed data from whole-exome sequencing of DNA of more than 10,000 individuals, unselected for cancer or hematologic phenoptypes [54,55].”
BackgroundSoerensen, J. F., Aggerholm, A., Kerndrup, G. B., Hansen, M. H., Ewald, I. K. L., Bill, M., Ebbesen, L. H., Rosenberg, C. A., Hokland, P., Ludvigsen, M., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2019001157 · Cited by 51
“CH has been shown to increase all-cause mortality, atherosclerosis, and the risk of developing de novo hematologic neoplasms, as well as tMN.(11-16) Moreover, in patients with CH, highdose conditioning regimens as part of treatment with ASCT have been shown to provide a proliferative advantage for mutated cell clones.”
BackgroundGenetic and Genomic Landscape of Secondary and Therapy-Related Acute Myeloid Leukemia
Higgins, A. S., & Shah, M. V. (2020) · Genes · doi:10.3390/genes11070749 · Cited by 56
High burden of clonal hematopoiesis in first responders exposed to the World Trade Center disaster
Jasra, S., Giricz, O., Zeig‐Owens, R., Pradhan, K., Goldfarb, D. G., Barreto-Galvez, A., Silver, A. J., Chen, J., Sahu, S., Gordon-Mitchell, S., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01708-3 · Cited by 55
The Role of Cell-Free DNA in Cancer Treatment Decision Making
Telekes, A., & Horváth, A. (2022) · Cancers · doi:10.3390/cancers14246115 · Cited by 58
“The frequency of clonal hematopoiesis of indeterminate potential (CHIP), as this phenomenon is termed, could increase significantly with age, and over the age of 70, may occur in more than 10% of patients [128,129].”
BackgroundHagiwara, K., Natarajan, S., Wang, Z., Zubair, H., Mulder, H. L., Dong, L., Plyler, E. M., Thimmaiah, P., Ma, X., Ness, K. K., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0956 · Cited by 53
Heimlich, J. B., Bhat, P., Parker, A. C., Jenkins, M. T., Vlasschaert, C., Ulloa, J., Van Amburg, J. C., Potts, C. R., Olson, S., Silver, A. J., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2023011445 · Cited by 42
“…thrombosis outcomes trial found that IL-1B antagonist, canakinu-mab, 38 reduced cardiovascular risk in TET2 but not patients with DNMT3A CH. 2,39 Our data provide a mechanistic rationale for a genotype-speci fi c approach to treat CH, a fi nding only possible with the ability to partition…”
BackgroundSteering research on mRNA splicing in cancer towards clinical translation
Anczuków, O., Allain, F. H. ‐., Angarola, B. L., Black, D. L., Brooks, A. N., Cheng, C., Conesa, A., Crosse, E. I., Eyras, E., Guccione, E., et al. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00750-2 · Cited by 59
“Recent data demonstrated that mutations in splicing factors occur very early during disease initiation and can act as founder mutations 27,191,192 .”
Guo, Y. P., Bosompem, A., Mohan, S. R., Erdoğan, B., Ye, F., Vickers, K. C., Sheng, Q., Zhao, S., Li, C.-I., Su, P.-F., et al. (2015) · BMC Genomics · doi:10.1186/s12864-015-1929-y · Cited by 53
“While this may simply point to underlying genomic instability of myeloid neoplasms, studies in acute myeloid leukemia have not generally found increased absolute numbers of mutations [74], and many mutations are found as a result of aging alone in individuals without any significant hematolymphoid malignancy [75–77].”
BackgroundPhenome and genome based studies into human ageing and longevity: An overview
Eline Slagboom, P., van den Berg, N., & Deelen, J. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2017.09.017 · Cited by 47
Gao, Y., Widschwendter, M., & Teschendorff, A. E. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.04.025 · Cited by 54
Uni, M., Masamoto, Y., Sato, T., Kamikubo, Y., Arai, S., Hara, E., & Kurokawa, M. (2018) · Leukemia · doi:10.1038/s41375-018-0198-6 · Cited by 55
Clonal hematopoiesis, aging, and cardiovascular diseases
Pardali, E., Dimmeler, S., Zeiher, A. M., & Rieger, M. A. (2019) · Experimental Hematology · doi:10.1016/j.exphem.2019.12.006 · Cited by 52
Physical activity, a modulator of aging through effects on telomere biology
Semeraro, M. D., Smith, C., Kaiser, M., Levinger, I., Duque, G., Gruber, H.-J., & Herrmann, M. (2020) · Aging · doi:10.18632/aging.103504 · Cited by 49
Schaefer, T., Steiner, R., & Lengerke, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21144902 · Cited by 55
“Leukemia, by contrast, arises from consecutive mutational hits within divisionally active HSPCs and their derived clonal lineages [84].”
BackgroundClonal hematopoiesis and its emerging effects on cellular therapies
Bonin, M. V., Jambor, H. K., Teipel, R., Stölzel, F., Thiede, C., Damm, F., Kroschinsky, F., Schetelig, J., Chavakis, T., & Bornhäuser, M. (2021) · Leukemia · doi:10.1038/s41375-021-01337-8 · Cited by 61
Functional and epigenetic phenotypes of humans and mice with DNMT3A Overgrowth Syndrome
Smith, A. M., LaValle, T. A., Shinawi, M. S., Ramakrishnan, S. M., Abel, H., Hill, C. A., Kirkland, N. M., Rettig, M. P., Helton, N., Heath, S. E., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24800-7 · Cited by 53
Indeterminate and oncogenic potential: CHIP vs CHOP mutations in AML with NPM1 alteration
Cappelli, L. V., Meggendorfer, M., Baer, C. R., Nadarajah, N., Hütter, S., Jeromin, S., Dicker, F., Kern, W., Haferlach, T., Haferlach, C., et al. (2021) · Leukemia · doi:10.1038/s41375-021-01368-1 · Cited by 55
“However, the presence of certain mutations in otherwise healthy subjects only confers a low risk for transformation [8, 9].”
BackgroundUncompromised 10-year survival of oldest old carrying somatic mutations in DNMT3A and TET2
van den Akker, E. B., Pitts, S. J., Deelen, J., Moed, M. H., Potluri, S., van Rooij, J., Suchiman, H. E. D., Lakenberg, N., de Dijcker, W. J., Uitterlinden, A. G., et al. (2016) · Blood · doi:10.1182/blood-2015-12-685925 · Cited by 49
“Recent large-scale sequencing studies report recurrent somatic mutations in the blood of elderly individuals in genes previously linked to clonal expansion of hematopoietic stem cells.(1-4) Particularly for DNMT3A andTET2, a steep age-associated increase in the prevalence of somatic mutations is observed from middle a…”
BackgroundMethodResultInfluentialA practical approach on the classifications of myeloid neoplasms and acute leukemia: WHO and ICC
Xiao, W., Nardi, V., Stein, E. M., & Hasserjian, R. P. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01571-4 · Cited by 59
“…(CHIP) refers to CH specifically harboring either a somatic mutation in a myeloid neoplasm driver gene with a variant allele frequency (VAF) of at least 2% or a non– MDS-defining clonal cytogenetic aberration, in a patient lacking a hematologic neoplasm or unexplained cyto-penia [12] (Table 2).”
BackgroundDiagnosis and Therapy of Acute Myeloid Leukemia in the Era of Molecular Risk Stratification
Komanduri, K. V., & Levine, R. L. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-051914-021329 · Cited by 51
Shen, W., Heeley, J. M., Carlston, C. M., Acuña‐Hidalgo, R., Nillesen, W. M., Dent, K. M., Douglas, G. V., Levine, K. L., Bayrak‐Toydemir, P., Marcelis, C., et al. (2017) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.38485 · Cited by 49
“However, they confer increased risk for subsequent development of a hematologic malignancy, which is likely due to a competitive growth advantage of variant-harboring cells and/or an increased susceptibility to the acquisition of additional somatic cancer-driver variants (Genovese et al., 2014; Papaemmanuil et al., 20…”
BackgroundInfluentialPapadopoulos, N. (2019) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-030-26439-0_9 · Cited by 54
Anande, G., Deshpande, N., Mareschal, S., Batcha, A. M. N., Hampton, H. R., Herold, T., Lehmann, S., Wilkins, M. R., Wong, J. W. H., Unnikrishnan, A., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0184 · Cited by 56
“8) as well as in healthy individuals with age-related clonal hematopoiesis (9).”
BackgroundSelf-citationCBL mutations drive PI3K/AKT signaling via increased interaction with LYN and PIK3R1
Belizaire, R., Koochaki, S., Udeshi, N. D., Vedder, A., Sun, L., Svinkina, T., Hartigan, C. R., McConkey, M. E., Kovalcik, V., Bizuayehu, A., et al. (2021) · Blood · doi:10.1182/blood.2020006528 · Cited by 55
Sequencing-based measurable residual disease testing in acute myeloid leukemia
Yoest, J. M., Shirai, C. L., & Duncavage, E. J. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00249 · Cited by 48
Rates and Patterns of Clonal Oncogenic Mutations in the Normal Human Brain
Ganz, J., Maury, E. A., Becerra, B., Bizzotto, S., Doan, R. N., Kenny, C. J., Shin, T., Kim, J., Zhou, Z., Ligon, K. L., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0245 · Cited by 48
“In our panel data, we found a surprising lack of age-related oncogenic variant accumulation in the brain, which differs from findings in other tissues (3–8).”
Mechanisms involved in hematopoietic stem cell aging
Fujino, T., Asada, S., Goyama, S., & Kitamura, T. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04356-5 · Cited by 56
“This results in either exhaustion, equilibrium, or expansion of the HSC clone over time [6, 237, 238].”
BackgroundGenotoxic aldehyde stress prematurely ages hematopoietic stem cells in a p53-driven manner
Wang, M., Brandt, L. T. L., Wang, X., Russell, H., Mitchell, E., Kamimae-Lanning, A. N., Brown, J. M., Dingler, F. A., Garaycoechea, J. I., Isobe, T., et al. (2023) · Molecular Cell · doi:10.1016/j.molcel.2023.05.035 · Cited by 56
Bronkhorst, A. J., & Holdenrieder, S. (2023) · Medizinische Genetik · doi:10.1515/medgen-2023-2065 · Cited by 81
Pathogenesis of Myeloproliferative Disorders
Nangalia, J., Grinfeld, J., & Green, A. R. (2016) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-012615-044454 · Cited by 54
Aplastic anemia and clonal evolution: germ line and somatic genetics
Shimamura, A. (2016) · Hematology · doi:10.1182/asheducation-2016.1.74 · Cited by 50
Changing mutational and adaptive landscapes and the genesis of cancer
Liggett, L. A., & DeGregori, J. V. (2017) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2017.01.005 · Cited by 55
RUNX1 cooperates with FLT3-ITD to induce leukemia
Behrens, K., Maul, K., Tekin, N. S., Kriebitzsch, N., Indenbirken, D., Prassolov, V., Müller, U., Serve, H. L., Cammenga, J., & Stocking, C. (2017) · The Journal of Experimental Medicine · doi:10.1084/jem.20160927 · Cited by 48
Clinical Outcomes and Co-Occurring Mutations in Patients with RUNX1-Mutated Acute Myeloid Leukemia
Khan, M., Cortes, J. E., Kadia, T. M., Naqvi, K. Z., Brandt, M., Pierce, S. A., Patel, K. P., Borthakur, G. M., Ravandi, F., Konopleva, M. Y., et al. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18081618 · Cited by 52
“Of interest, clonal expansion of ASXL1 is one of the most frequently identified genes in age-related clonal hematopoiesis, and subsequent RUNX1 mutations may be implicated in malignant progression in these individuals [21,22].”
BackgroundFukumoto, K., Nguyen, T. B., Chiba, S., & Sakata‐Yanagimoto, M. (2017) · Cancer Science · doi:10.1111/cas.13393 · Cited by 51
“Finally, somatic mutations were also detected even in healthy individuals.(19,20) Mutation frequencies were reportedly increased with age: by 5% for those in their 60s, by 10% to 15% for those in their 70s, and by 10% to 25% for those in their 80s.”
BackgroundInfluentialImpact of aging on bone, marrow and their interactions
Hoffman, C. M., Han, J., & Calvi, L. M. (2018) · Bone · doi:10.1016/j.bone.2018.07.012 · Cited by 49
Metadata
- Authors
- Genovese, G., Kähler, A. K., Handsaker, R. E., Lindberg, J., Rose, S. A., Bakhoum, S. F., Chambert, K., Mick, E., Neale, B. M., Fromer, M., Purcell, S. M., Svantesson, O., Landén, M., Höglund, M., Lehmann, S., Gabriel, S. B., Moran, J. L., Lander, E. S., Sullivan, P. F., Sklar, P., Grönberg, H., Hultman, C. M., & McCarroll, S. A.
- Affiliations
- Harvard University (US)
- Karolinska Institutet (SE)
- Science for Life Laboratory (SE)
- Stanley Center for Psychiatric Research (US)
- Memorial Sloan Kettering Cancer Center (US)
- Massachusetts General Hospital (US)
- Icahn School of Medicine at Mount Sinai (US)
- University of Gothenburg (SE)
- Uppsala University Hospital (SE)
- Karolinska University Hospital (SE)
- Broad Institute (US)
- University of North Carolina at Chapel Hill (US)
- ORCID
- Genovese, Giulio
- Kähler, Anna K.
- Handsaker, Robert E.
- Lindberg, Johan
- Rose, Samuel A.
- Bakhoum, Samuel F.
- Mick, Eran
- Neale, Benjamin M.
- Fromer, Menachem
- Purcell, Shaun M.
- Landén, Mikael
- Höglund, Martin
- Lehmann, Sören
- Gabriel, Stacey B.
- Moran, Jennifer L.
- Lander, Eric S.
- Sullivan, Patrick F.
- Sklar, Pamela
- Grönberg, Henrik
- McCarroll, Steven A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-12-25
- Volume
- 371
- Issue
- 26
- Pages
- 2477-2487
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4290021
- OpenAlex
- W2126816979
- Cited by
- 3,531
- References
- 40
- Citations by year
- 2026: 240 · 2025: 293 · 2024: 315 · 2023: 363 · 2022: 386 · 2021: 360 · 2020: 356 · 2019: 310 · 2018: 294 · 2017: 254 · 2016: 215 · 2015: 134 · 2014: 6
- FWCI
- 143.98
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute of Mental Health (R01MH077139, RC2MH089905)
- National Human Genome Research Institute (R01HG006855, U54HG003067, R01HG005827)
- National Cancer Institute (P30CA014051)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Epidemiology › Multiple and Secondary Primary Cancers
- Keywords
- clonal hematopoiesis, somatic mutations, DNMT3A, ASXL1, TET2, acute myeloid leukemia, early cancer detection, bone marrow biopsy, cancer susceptibility
- MeSH terms
- Adult, Age Factors, Aged, Aged, 80 and over, Blood, Cell Transformation, Neoplastic, Clone Cells, DNA Mutational Analysis, Hematopoiesis, Hematopoietic Stem Cells, Humans, Middle Aged, Mutation, Risk Factors, Hematologic Neoplasms, Young Adult, Exome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.